[{"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124-001", "question": "A 34-year-old woman presents with 6 months of progressive bilateral hand weakness and numbness. She has a 15-year history of systemic lupus erythematosus treated with hydroxychloroquine and low-dose prednisone. Examination reveals symmetric weakness of finger abduction and adduction bilaterally, decreased sensation to pinprick over the ulnar aspect of both hands, and absent ulnar deep tendon reflexes. Nerve conduction studies show reduced compound muscle action potential amplitudes in bilateral ulnar nerves with conduction block at the elbow, prolonged distal motor latencies, and temporal dispersion. Anti-ganglioside antibodies are negative. CSF shows protein 85 mg/dL with 2 WBCs. Which of the following is the most likely diagnosis?", "options": ["Multifocal motor neuropathy with conduction block", "Chronic inflammatory demyelinating polyneuropathy", "Lupus-associated mononeuritis multiplex", "Lewis-Sumner syndrome", "Hereditary neuropathy with liability to pressure palsies"], "answer": "D", "answer_index": 3, "explanation": "Lewis-Sumner syndrome (multifocal acquired demyelinating sensory and motor neuropathy, MADSAM) is characterized by asymmetric sensorimotor involvement with demyelinating features including conduction block, distinguishing it from multifocal motor neuropathy (purely motor, anti-GM1 positive) and CIDP (symmetric). The presence of sensory symptoms and signs excludes MMN. Lupus mononeuritis multiplex typically shows axonal rather than demyelinating features. HNPP would show conduction abnormalities at typical compression sites without temporal dispersion.", "generator_model": "claude-opus-4-5-20251101", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "D", "model_outputs": "This patient presents with a progressive, sensorimotor neuropathy affecting the upper limbs with a specific distribution (ulnar nerves) and evidence of demyelination with conduction block.\n\n1.  Clinical Features: The patient has weakness in finger abduction/adduction (ulnar motor) and numbness in the ulnar distribution. This is a sensorimotor presentation.\n2.  Electrophysiology: The nerve conduction studies show focal demyelination (conduction block) specifically at the elbow, along with signs of demyelination (prolonged latencies, temporal dispersion).\n3.  CSF: The CSF protein is elevated (albuminocytologic dissociation), consistent with an inflammatory demyelinating neuropathy.\n4.  Excluding Options:\n    *   A. Multifocal motor neuropathy (MMN): MMN is characterized by pure motor deficits and conduction blocks. The presence of significant sensory symptoms (\"numbness\", \"decreased sensation to pinprick\") effectively rules out MMN.\n    *   B. Chronic inflammatory demyelinating polyneuropathy (CIDP): Classic CIDP typically presents with symmetric, proximal and distal weakness, often starting in the lower extremities. This patient has a restricted upper limb, distal, nerve-specific presentation.\n    *   C. Lupus-associated mononeuritis multiplex: This condition is caused by vasculitis, which results in ischemic nerve damage. The electrophysiology would demonstrate axonal loss (reduced amplitudes without focal slowing or block), not the demyelinating features (conduction block) seen here.\n    *   E. Hereditary neuropathy with liability to pressure palsies (HNPP): While HNPP causes conduction blocks at entrapment sites (like the ulnar nerve at the elbow), it is a hereditary condition usually presenting with recurrent, episodic palsies. Furthermore, CSF protein in HNPP is typically normal. The subacute progressive course and high protein favor an acquired inflammatory etiology.\n    *   D. Lewis-Sumner syndrome (LSS): Also known as Multifocal Acquired Demyelinating Sensory and Motor neuropathy (MADSAM). It is considered a variant of CIDP but presents with a multifocal (or asymmetric) pattern in the distribution of individual nerves (resembling mononeuritis multiplex) and affects the upper limbs predominantly. Importantly, it involves both sensory and motor fibers, distinguishing it from MMN, and has conduction blocks, distinguishing the pattern from classic length-dependent polyneuropathies. Although typically asymmetric, symmetric presentations can occur or mimic bilateral entrapments.\n\nThe presence of conduction block in the context of acquired, sensorimotor, distal upper limb neuropathy is the classic description of Lewis-Sumner syndrome.\n\nThe answer is (D)"}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124-002", "question": "A 28-year-old woman at 32 weeks gestation presents with sudden onset severe headache, visual disturbances, and confusion. Blood pressure is 178/112 mmHg. Laboratory studies show platelets 68,000/μL, LDH 890 U/L, AST 245 U/L, creatinine 1.8 mg/dL, and peripheral smear with schistocytes. She receives magnesium sulfate and labetalol. Emergent cesarean delivery is performed. Postpartum day 3, despite delivery, her platelet count drops to 42,000/μL, creatinine rises to 2.9 mg/dL, and she develops new neurological symptoms. ADAMTS13 activity returns at 58%. Which additional finding would most strongly support initiating eculizumab therapy?", "options": ["Positive direct antiglobulin test", "Complement factor H mutation on genetic testing", "Elevated soluble fms-like tyrosine kinase-1 levels", "Low C3 with normal C4 levels", "Presence of anti-phospholipid antibodies"], "answer": "B", "answer_index": 1, "explanation": "This presentation of postpartum thrombotic microangiopathy not resolving after delivery with ADAMTS13 >10% suggests complement-mediated TMA (atypical HUS) rather than TTP or HELLP syndrome. Complement factor H mutation confirms complement dysregulation and strongly supports eculizumab (C5 inhibitor) therapy. Low C3 with normal C4 suggests alternative pathway activation but is nonspecific. Elevated sFlt-1 would suggest ongoing preeclampsia-related pathology. Positive DAT would suggest Evans syndrome, and anti-phospholipid antibodies suggest catastrophic APS, both requiring different management.", "generator_model": "claude-opus-4-5-20251101", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "The clinical presentation is consistent with a Thrombotic Microangiopathy (TMA). The key features are severe hypertension, microangiopathic hemolytic anemia (schistocytes, elevated LDH), thrombocytopenia, and renal failure.\n\nThe differential diagnosis for TMA in pregnancy and the postpartum period primarily includes:\n1.  Preeclampsia with severe features / HELLP syndrome: This is the most common cause. However, these conditions typically begin to resolve within 24-48 hours after delivery. The patient's worsening clinical status (platelets dropping, creatinine rising, new neuro symptoms) on postpartum day 3 despite delivery \"unmasks\" an alternative diagnosis and argues against HELLP.\n2.  Thrombotic Thrombocytopenic Purpura (TTP): Characterized by severe ADAMTS13 deficiency (<10%). This patient has a level of 58%, which effectively rules out TTP.\n3.  Atypical Hemolytic Uremic Syndrome (aHUS): This is a complement-mediated TMA. Pregnancy is a known trigger. The clinical course of worsening renal failure and thrombocytopenia postpartum is classic for pregnancy-associated aHUS. Eculizumab (a terminal complement inhibitor) is the treatment of choice.\n\nLet's evaluate the findings that would support the diagnosis of aHUS and the use of eculizumab:\n*   A. Positive direct antiglobulin test: This would suggest autoimmune hemolytic anemia, not a TMA. aHUS is Coombs-negative.\n*   B. Complement factor H mutation on genetic testing: Mutations in complement regulatory genes (most commonly Factor H) are the underlying cause of aHUS in the majority of identified genetic cases. Finding a pathogenic mutation confirms the diagnosis of complement-mediated TMA and provides the strongest mechanistic support for using eculizumab, which targets the dysregulated complement pathway.\n*   C. Elevated soluble fms-like tyrosine kinase-1 (sFlt-1) levels: Extremely high sFlt-1 levels are characteristic of preeclampsia/HELLP caused by placental pathology. In contrast, sFlt-1 levels are typically lower in patients with primary TMAs like aHUS or TTP. Therefore, an elevated level would support a diagnosis of HELLP (which is treated supportively) rather than aHUS, arguing *against* the specific need for eculizumab (though clinical overlap exists, diagnostic distinction is the goal here).\n*   D. Low C3 with normal C4 levels: This pattern indicates activation of the alternative complement pathway, which is consistent with aHUS. However, serum C3 levels are low in only about 30-50% of patients with aHUS; normal levels do not rule out the disease. While suggestive, it is less definitive than the genetic mutation.\n*   E. Presence of anti-phospholipid antibodies: This would support a diagnosis of Catastrophic Antiphospholipid Syndrome (CAPS), which is primarily treated with anticoagulation, corticosteroids, and plasma exchange.\n\nOption B is the most specific finding for the etiology that eculizumab treats (complement dysregulation). Although genetic testing results may take time, the *finding* itself provides the strongest confirmation of the indication for therapy compared to the other options.\n\nThe answer is (B)"}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124-003", "question": "A 52-year-old man with hypertrophic cardiomyopathy and an ICD presents with recurrent appropriate shocks for ventricular tachycardia despite maximum tolerated doses of metoprolol and disopyramide. Echocardiogram shows septal thickness of 22 mm, LVOT gradient of 85 mmHg at rest, and moderate mitral regurgitation with systolic anterior motion. Cardiac MRI demonstrates 18% late gadolinium enhancement predominantly in the septum. Coronary angiography is normal. Which intervention is most likely to reduce his arrhythmia burden?", "options": ["Alcohol septal ablation", "Surgical septal myectomy with mitral valve repair", "Catheter ablation of ventricular tachycardia", "Addition of amiodarone to current regimen", "Cardiac transplantation evaluation"], "answer": "B", "answer_index": 1, "explanation": "In HCM patients with significant LVOT obstruction, extensive LGE (>15%), and recurrent VT, surgical myectomy is preferred over alcohol septal ablation because ASA creates additional scar that may be proarrhythmic. Myectomy reduces obstruction and allows concomitant mitral valve repair for SAM-related MR. The extensive LGE indicates high arrhythmic substrate burden. VT ablation addresses the arrhythmia but not the underlying obstruction driving symptoms. Amiodarone adds toxicity risk without addressing mechanism. Transplant is premature given available surgical options.", "generator_model": "claude-opus-4-5-20251101", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "This patient has obstructive hypertrophic cardiomyopathy (HCM) with a severe resting left ventricular outflow tract (LVOT) gradient (85 mmHg) and recurrent ventricular tachycardia (VT) resulting in appropriate ICD shocks despite optimal medical therapy (beta-blocker and disopyramide). He also has significant septal fibrosis identified by late gadolinium enhancement (LGE).\n\nAnalysis of the Options:\n\n*   A. Alcohol septal ablation: This procedure reduces the LVOT gradient by inducing a controlled localized myocardial infarction in the basal septum. While it is effective for symptom relief in obstruction, it creates a scar (fibrosis), which can serve as a substrate for ventricular re-entrant arrhythmias. In a patient who already has recurrent VT and high scar burden, adding more scar tissue is generally less desirable than removing it.\n*   B. Surgical septal myectomy with mitral valve repair: This is the gold standard therapy for drug-refractory obstructive HCM. In patients with obstructive HCM and recurrent VT, surgical myectomy provides a twofold benefit: 1) It relieves the LVOT obstruction, thereby significantly reducing left ventricular wall stress and myocardial oxygen demand (ischemia is a trigger for VT). 2) It physically resects the hypertrophied septal muscle, which often contains the fibrosis/scar tissue (LGE) that acts as the arrhythmogenic substrate. Observational studies have demonstrated that surgical myectomy significantly reduces the burden of recurrent VT and the frequency of appropriate ICD shocks.\n*   C. Catheter ablation of ventricular tachycardia: Catheter ablation in HCM is challenging because the arrhythmic substrate is often intramural or extensive. While it may be used as an adjunctive therapy, success rates are lower than in ischemic cardiomyopathy, and it does not address the severe hemodynamic obstruction driving the cardiac stress.\n*   D. Addition of amiodarone: While amiodarone is a potent antiarrhythmic, the patient is already on maximal medical therapy including disopyramide. Combining disopyramide (QT-prolonging) with amiodarone increases the risk of pro-arrhythmia and side effects. Furthermore, medical therapy does not correct the severe anatomical obstruction.\n*   E. Cardiac transplantation evaluation: This is reserved for patients with end-stage heart failure or arrhythmia refractory to all other surgical and catheter-based interventions. Since this patient has a surgically correctable obstruction, myectomy is the appropriate next step before considering transplant.\n\nTherefore, surgical myectomy is the intervention most likely to reduce the arrhythmia burden by relieving the hemodynamic trigger and resecting the arrhythmogenic substrate.\n\nThe answer is (B)"}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124-004", "question": "A 45-year-old woman with dermatomyositis diagnosed 8 months ago presents with progressive dyspnea. She was initially treated with high-dose prednisone and azathioprine with improvement in proximal muscle weakness. CT chest shows new ground-glass opacities with peripheral consolidation in lower lobes. Pulmonary function tests reveal FVC 58% predicted, DLCO 42% predicted. Bronchoalveolar lavage shows 35% lymphocytes. She tests positive for anti-MDA5 antibodies. Which treatment approach offers the best chance of halting disease progression?", "options": ["Increase prednisone and add mycophenolate mofetil", "Triple therapy with high-dose glucocorticoids, calcineurin inhibitor, and cyclophosphamide", "Rituximab with continued azathioprine", "Nintedanib with continued current immunosuppression", "Plasma exchange followed by IVIG maintenance"], "answer": "B", "answer_index": 1, "explanation": "Anti-MDA5 dermatomyositis-associated rapidly progressive interstitial lung disease carries high mortality and requires aggressive upfront combination immunosuppression. Japanese and international experience supports triple therapy with high-dose corticosteroids, a calcineurin inhibitor (tacrolimus or cyclosporine), and cyclophosphamide as the most effective approach for halting progression. Single-agent additions or rituximab have shown inferior outcomes in this specific antibody subset. Nintedanib is antifibrotic, not immunosuppressive. Plasma exchange lacks evidence in this context.", "generator_model": "claude-opus-4-5-20251101", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "This patient has dermatomyositis with interstitial lung disease (ILD) and is positive for anti-MDA5 antibodies. The presence of anti-MDA5 antibodies is a critical prognostic marker, strongly associated with rapidly progressive interstitial lung disease (RP-ILD) and a high mortality rate due to respiratory failure. Moreover, she is currently progressing (worsening dyspnea, new ground-glass opacities, declining lung function) despite treatment with prednisone and azathioprine.\n\nGiven the high mortality and rapid progression associated with anti-MDA5 ILD, standard stepwise escalation of immunosuppression is often insufficient. Recent observational studies and expert consensus support the use of upfront aggressive combination therapy (often referred to as \"triple therapy\") to improve survival rates. This regimen typically consists of high-dose glucocorticoids, a calcineurin inhibitor (such as tacrolimus or cyclosporine), and intravenous cyclophosphamide.\n\nWhile mycophenolate mofetil (Option A) and rituximab (Option C) are used in myositis-associated ILD, the specific high-risk profile of anti-MDA5 warrants the rapid and potent immunomodulation provided by the combination of a calcineurin inhibitor and cyclophosphamide. Nintedanib (Option D) addresses fibrosis but does not treat the underlying active inflammation driving the rapid progression. Plasma exchange (Option E) is considered salvage therapy rather than the primary approach for halting progression.\n\nTherefore, the aggressive \"triple therapy\" approach offers the best chance of halting disease progression and improving survival in this specific clinical context.\n\nThe answer is (B)"}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124-005", "question": "A 38-year-old man from Cambodia presents with 3 weeks of fever, headache, and altered mental status. CSF analysis shows opening pressure 32 cm H2O, WBC 180/μL (90% lymphocytes), protein 120 mg/dL, glucose 28 mg/dL (serum 110 mg/dL). India ink preparation shows encapsulated yeast. Cryptococcal antigen titer is 1:2048 in CSF. HIV testing is positive with CD4 count of 35 cells/μL. He is started on liposomal amphotericin B and flucytosine with daily therapeutic lumbar punctures. On day 10, repeat lumbar puncture shows opening pressure 38 cm H2O, CSF WBC 420/μL (85% lymphocytes), protein 180 mg/dL, and cryptococcal antigen titer 1:1024. He has worsening headache and new sixth nerve palsy. What is the most appropriate next step?", "options": ["Add dexamethasone for paradoxical immune reconstitution inflammatory syndrome", "Switch to high-dose fluconazole for amphotericin resistance", "Place a ventriculoperitoneal shunt for refractory elevated intracranial pressure", "Continue current antifungal therapy with more aggressive CSF drainage", "Initiate antiretroviral therapy immediately to improve immune function"], "answer": "D", "answer_index": 3, "explanation": "The rising CSF pleocytosis with persistent elevated opening pressure despite treatment represents ongoing cryptococcal meningitis with inadequate pressure management rather than treatment failure or IRIS (patient not yet on ART). The antigen titer is decreasing appropriately. Management requires more aggressive CSF drainage-either more frequent LPs or temporary lumbar drain placement. Corticosteroids are contraindicated in cryptococcal meningitis (increased mortality in COAT trial). VPS is reserved for truly refractory cases after optimizing medical management. Early ART initiation increases IRIS risk and mortality when started before 4-6 weeks of antifungal therapy.", "generator_model": "claude-opus-4-5-20251101", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "D", "model_outputs": "This patient is a 38-year-old male with HIV (CD4 35 cells/μL) diagnosed with Cryptococcal meningitis. He was started on appropriate induction therapy (liposomal amphotericin B and flucytosine) and has been receiving daily lumbar punctures (LPs) for elevated intracranial pressure (ICP). On day 10, despite this management, he has worsening headache, persistent elevated opening pressure (38 cm H2O), and a new abducens (sixth) nerve palsy.\n\nThe clinical picture describes refractory elevated intracranial pressure in the setting of cryptococcal meningitis. Worsening headache and new focal neurologic deficits (like VI nerve palsy) are classic signs of uncontrolled ICP. The sixth nerve is successfully vulnerable to stretching due to high intracranial pressure, serving as a \"false localizing sign.\"\n\nThe management of elevated ICP in cryptococcal meningitis follows a stepwise approach:\n1.  Therapeutic Lumbar Punctures: Daily LPs are standard initial management to maintain opening pressure <20 cm H2O or 50% of the initial pressure.\n2.  Continuous Drainage: If daily LPs are insufficient to control pressure or symptoms (refractory ICP), or if the patient cannot tolerate daily LPs, more aggressive mechanical drainage is required. This is typically achieved via a temporary lumbar drain or an external ventricular drain (EVD).\n3.  Permanent Shunting: A ventriculoperitoneal (VP) shunt is generally reserved for patients with non-communicating hydrocephalus or those who require drainage for an extended period (weeks) after the acute infection has been controlled. Converting to a permanent shunt during the acute phase (Day 10) with active infection carries a high risk of shunt infection and failure.\n\nOption D is the best answer. Continuing the current antifungal regimen (which is the gold standard induction therapy) is correct. \"More aggressive CSF drainage\" appropriately describes the escalation from daily LPs to measures such as a continuous lumbar drain or more frequent drainage to control the refractory pressure and resolve the focal deficit.\n\nOption A is incorrect because corticosteroids (dexamethasone) have been shown to not improve mortality and are associated with more adverse events and disability in HIV-associated cryptococcal meningitis (CRYPTO-DEX trial). They are not used for ICP management.\nOption B is incorrect because amphotericin resistance is rare, and switching to fluconazole (a fungistatic agent) during the induction phase would be a downgrade in therapy.\nOption C is less appropriate than D because immediate placement of a permanent VP shunt in a patient with active fungal meningitis (Day 10) is risky. Temporary drainage (covered under \"more aggressive drainage\") is the preferred bridge.\nOption E is incorrect because initiating antiretroviral therapy (ART) this early (Day 10) is associated with a high risk of fatal Immune Reconstitution Inflammatory Syndrome (IRIS). ART is typically delayed for 4-6 weeks.\n\nThe answer is (D)"}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124-006", "question": "A 67-year-old woman with longstanding rheumatoid arthritis on methotrexate and adalimumab develops progressive cognitive decline over 4 months. MRI brain shows multifocal white matter lesions without enhancement or mass effect. CSF shows 8 WBCs (all lymphocytes), protein 62 mg/dL, and negative routine cultures. JC virus PCR in CSF is positive with 850 copies/mL. Adalimumab is discontinued. Three weeks later, she develops new right hemiparesis and worsening confusion. Repeat MRI shows enlargement of lesions with new peripheral enhancement and edema. CSF now shows 45 WBCs (predominantly lymphocytes). What is the most appropriate management?", "options": ["Restart adalimumab to suppress destructive inflammation", "Initiate high-dose corticosteroids", "Begin cidofovir and cytarabine combination therapy", "Administer pembrolizumab to enhance JC virus clearance", "Perform brain biopsy to exclude CNS lymphoma"], "answer": "B", "answer_index": 1, "explanation": "This patient has developed immune reconstitution inflammatory syndrome (IRIS) following discontinuation of immunosuppression in the setting of PML. The new enhancement, edema, and increased CSF pleocytosis after stopping adalimumab are classic for PML-IRIS. High-dose corticosteroids are indicated to reduce the inflammatory response that, while representing immune recovery, can cause significant neurological damage. Restarting immunosuppression would be counterproductive. Cidofovir/cytarabine lack efficacy in PML. Pembrolizumab is used in refractory PML without immune reconstitution, not IRIS. Biopsy is unnecessary given confirmed JC virus and classic IRIS presentation.", "generator_model": "claude-opus-4-5-20251101", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "Based on the clinical presentation, the patient initially presented with Progressive Multifocal Leukoencephalopathy (PML) confirmed by the presence of JC virus DNA in the CSF and characteristic MRI findings in the context of immunosuppressive therapy (adalimumab and methotrexate).\n\nFollowing the discontinuation of adalimumab, the patient's condition worsened with new neurological deficits, and the MRI showed new enhancement and edema, while CSF pleocytosis increased. This temporal sequence and widespread inflammation upon withdrawal of immunosuppression are characteristic of PML-Immune Reconstitution Inflammatory Syndrome (PML-IRIS). The immune system, no longer suppressed, mounts an exuberant inflammatory response against the JC virus, leading to edema and blood-brain barrier breakdown (enhancement).\n\nThe management of severe PML-IRIS, particularly when there is significant cerebral edema or neurological deterioration, involves the use of corticosteroids to reduce the inflammatory response and mass effect.\n\n*   Option A: Restarting adalimumab is not the standard treatment for IRIS and would essentially leave the patient immunosuppressed, hindering clearance of the JC virus.\n*   Option B: High-dose corticosteroids are the recommended treatment for symptomatic PML-IRIS to dampen the excessive inflammation and manage cerebral edema.\n*   Option C: Cidofovir and cytarabine have failed to show efficacy in clinical trials for PML and are not standard care.\n*   Option D: Pembrolizumab is a checkpoint inhibitor sometimes used to *boost* the immune response in patients with PML who cannot mount one (e.g., idiopathic lymphopenia). Using it in IRIS (where the immune response is already excessive) would likely be harmful.\n*   Option E: A biopsy is generally not necessary when the diagnosis of PML has been confirmed by PCR and the clinical course fits the classic pattern of IRIS following immune reconstitution.\n\nThe answer is (B)"}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124-007", "question": "A 29-year-old woman presents with 2 years of recurrent oral ulcers, genital ulcers, and bilateral anterior uveitis. She now develops sudden painless vision loss in her right eye. Examination reveals visual acuity of hand motion OD and 20/25 OS. Fundoscopy of the right eye shows diffuse retinal whitening with cherry-red spot and box-carring in retinal arterioles. Fluorescein angiography confirms central retinal artery occlusion. HLA-B51 is positive. Pathergy test is negative. What is the most appropriate immediate intervention to prevent contralateral involvement?", "options": ["High-dose intravenous methylprednisolone alone", "Infliximab infusion", "Combination of high-dose corticosteroids with cyclosporine", "Combination of high-dose corticosteroids with infliximab or adalimumab", "Anterior chamber paracentesis with ocular massage"], "answer": "D", "answer_index": 3, "explanation": "This patient has Behçet disease with ocular involvement including the devastating complication of retinal artery occlusion from retinal vasculitis. Immediate aggressive immunosuppression is critical to prevent bilateral blindness. Current evidence supports combination therapy with high-dose corticosteroids plus a TNF-alpha inhibitor (infliximab or adalimumab) as the most effective approach for severe ocular Behçet. Corticosteroids alone or with cyclosporine are insufficient for this severity. Anterior chamber paracentesis addresses embolic CRAO, not inflammatory vasculitic occlusion. The goal is preventing contralateral involvement through rapid inflammation control.", "generator_model": "claude-opus-4-5-20251101", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "D", "model_outputs": "This patient presents with signs and symptoms consistent with Behçet's disease (recurrent oral and genital ulcers, uveitis, positive HLA-B51) complicated by a Central Retinal Artery Occlusion (CRAO). The CRAO in this context is likely due to active retinal vasculitis and thrombosis associated with the systemic disease. This is a severe, sight-threatening emergency.\n\nThe primary goal in managing severe ocular manifestations of Behçet's disease, such as retinal vasculitis and vaso-occlusive events, is to rapidly control inflammation to preserve any remaining vision in the affected eye and, crucially, to prevent involvement and blindness in the contralateral eye.\n\n1.  Immediate Inflammation Control: High-dose corticosteroids (often pulse intravenous methylprednisolone) are the standard immediate intervention to quell acute inflammation.\n2.  Long-term Control and Prevention: Corticosteroids alone are insufficient for maintaining remission and preventing damage in severe ocular Behçet's disease. Current guidelines, including the EULAR recommendations, support the early use of anti-TNF alpha agents (such as infliximab or adalimumab) for patients with severe, sight-threatening uveitis or retinal vasculitis. These agents have been shown to be superior to traditional immunosuppressants (like cyclosporine or azathioprine) in achieving rapid remission and preventing relapses.\n3.  Combination Therapy: In the setting of an acute, severe attack (like a vascular occlusion), the standard of care is to combine high-dose corticosteroids (for immediate effect) with an anti-TNF agent (for potent, sustained disease modification). This combination offers the best chance of arresting the systemic vasculitic process and protecting the fellow eye.\n\nTherefore:\n*   Option A is insufficient because steroids alone do not provide adequate long-term control.\n*   Option C uses cyclosporine, which is generally considered less effective than anti-TNF agents for severe posterior segment involvement in Behçet's disease.\n*   Option E addresses the mechanical obstruction of a typical embolic CRAO but does not address the underlying systemic vasculitis causing the occlusion in this patient and will not protect the other eye.\n*   Option D represents the most appropriate, aggressive, evidence-based intervention for severe, sight-threatening ocular Behçet's disease.\n\nThe answer is (D)"}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124-008", "question": "A 41-year-old man with no significant medical history presents with 6 weeks of progressive bilateral lower extremity weakness and paresthesias. He reports a diarrheal illness 8 weeks ago. Examination shows 3/5 strength in hip flexors, 4/5 in knee extensors, 4-/5 in ankle dorsiflexors bilaterally, absent deep tendon reflexes, and decreased vibration sense to the knees. Nerve conduction studies show reduced CMAP amplitudes with normal conduction velocities and no conduction block. Needle EMG shows active denervation in distal leg muscles. CSF protein is 95 mg/dL with 1 WBC. Anti-GM1 IgG antibodies are strongly positive. Despite 5 days of IVIG, he continues to worsen with new respiratory compromise requiring intubation. What is the next best step in management?", "options": ["Repeat IVIG course immediately", "Initiate plasma exchange", "Add high-dose intravenous methylprednisolone", "Begin eculizumab therapy", "Administer second IVIG course after 4-week interval"], "answer": "B", "answer_index": 1, "explanation": "This patient has acute motor axonal neuropathy (AMAN) variant of Guillain-Barré syndrome, evidenced by pure motor axonal pattern on NCS, anti-GM1 antibodies, and preceding Campylobacter-like illness. When patients fail to respond to initial IVIG and continue deteriorating, plasma exchange is the appropriate next step as it works through a different mechanism (antibody removal vs. immunomodulation). The treatments are not synergistic when given together but can be used sequentially. Corticosteroids are ineffective in GBS. Eculizumab has shown promise in refractory cases but is not yet standard of care. Waiting 4 weeks for repeat IVIG is inappropriate in a deteriorating patient.", "generator_model": "claude-opus-4-5-20251101", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "D", "model_outputs": "The clinical presentation and workup are consistent with Acute Motor Axonal Neuropathy (AMAN), a subtype of Guillain-Barré Syndrome (GBS).\n*   Support for AMAN: The patient has a history of diarrheal illness (likely *Campylobacter jejuni*), motor-predominant features (though sensory findings can occur), Anti-GM1 IgG antibodies (highly specific for AMAN), and EDX showing reduced CMAP amplitudes with normal conduction velocities (axonal pattern).\n*   The Problem: The patient has failed the initial course of IVIG (treatment-related fluctuation or primary progression) and is deteriorating with respiratory compromise.\n*   Analysis of Options:\n    *   A. Repeat IVIG course immediately: Recent pivotal trials, specifically the SID-GBS trial, showed that a second course of IVIG in patients with severe GBS or poor prognosis does *not* improve outcomes compared to placebo. Therefore, guidelines generally recommend against repeating IVIG, although it is sometimes done in practice due to lack of alternatives.\n    *   B. Initiating plasma exchange (PLEX): Performing PLEX after IVIG is generally contraindicated because it would wash out the administered immunoglobulins, negating the first treatment.\n    *   C. Add high-dose intravenous methylprednisolone: Corticosteroids are not effective in GBS/AMAN and can be detrimental. While progression beyond 4-8 weeks might suggest CIDP (which responds to steroids), the patient's specific serology (Anti-GM1) and axonal electrophysiology are characteristic of AMAN, not CIDP. Therefore, steroids are not the best mechanism-based choice.\n    *   D. Begin eculizumab therapy: The pathophysiology of AMAN involves Complement-mediated injury (specifically via the Membrane Attack Complex) at the Nodes of Ranvier, triggered by Anti-GM1 antibodies. Eculizumab is a C5/complement inhibitor. Clinical trials (e.g., JET-GBS) have demonstrated efficacy specifically in severe GBS patients, with the greatest benefit seen in the subgroup with Anti-GM1 antibodies (AMAN). Although regulatory approval varies by country (approved in Japan, orphan status in others), in the context of a board examination query presenting a refractory Anti-GM1+ patient, this is the most scientifically sound, mechanism-targeted \"next step\" supported by trial data for this specific phenotype.\n\nThe answer is (D)"}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124-009", "question": "A 55-year-old woman with mechanical mitral valve replacement on warfarin presents with acute onset aphasia and right hemiplegia. Symptoms began 90 minutes ago. CT head shows no hemorrhage. CT angiography reveals left M1 occlusion. INR is 2.8. CT perfusion shows large penumbra with small core infarct (ASPECTS 8). Blood pressure is 165/95 mmHg. What is the most appropriate next step?", "options": ["Administer IV alteplase followed by endovascular thrombectomy", "Proceed directly to endovascular thrombectomy without IV thrombolysis", "Reverse anticoagulation with 4-factor PCC then administer IV alteplase", "Administer idarucizumab followed by IV alteplase", "Medical management only with blood pressure optimization"], "answer": "B", "answer_index": 1, "explanation": "In patients with acute ischemic stroke on therapeutic anticoagulation (INR >1.7), IV thrombolysis is contraindicated due to bleeding risk. However, mechanical thrombectomy is not contraindicated and should be pursued emergently in patients with large vessel occlusion and favorable perfusion imaging (large penumbra, small core). Reversing anticoagulation to give tPA adds delay and the combination increases bleeding risk. Idarucizumab reverses dabigatran, not warfarin. Medical management alone would result in completed large territory infarction given the M1 occlusion. Direct thrombectomy offers the best risk-benefit profile.", "generator_model": "claude-opus-4-5-20251101", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "Here is the step-by-step reasoning for the best answer:\n\n1.  Assess eligibility for IV Thrombolysis (Alteplase): The patient presents within the therapeutic window for IV thrombolysis (90 minutes from onset, well within the 4.5-hour limit). However, she is taking warfarin and has an INR of 2.8. According to current AHA/ASA guidelines, IV alteplase is contraindicated in patients taking vitamin K antagonists (like warfarin) if the INR is > 1.7. Therefore, options A, C, and D are incorrect regarding the administration of alteplase. Specifically, Option C (reversal to give tPA) is not standard care and delays definitive treatment, and Option D involves idarucizumab, which reverses dabigatran, not warfarin.\n\n2.  Assess eligibility for Endovascular Thrombectomy (EVT): The patient has a blockage in a large vessel (Left M1 occlusion) and favorable imaging findings (ASPECTS 8, large penumbra with small core). She is within the time window for mechanical thrombectomy (0-6 hours for standard criteria, up to 24 hours for tissue-window criteria).\n\n3.  Determine the best management strategy: Since the patient is eligible for mechanical thrombectomy but contraindicated for IV alteplase due to the supratherapeutic INR (in the context of stroke lysis guidelines), the most appropriate next step is to proceed directly to mechanical thrombectomy. This avoids the bleeding risks associated with tPA in a coagulopathic patient while addressing the occlusion to salvage brain tissue. Medical management alone (Option E) is inferior to thrombectomy for large vessel occlusions with salvageable tissue.\n\nThe answer is (B)"}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124-010", "question": "A 33-year-old woman with no prior cardiac history presents with progressive exertional dyspnea over 3 months. She delivered her third child 5 months ago. Echocardiogram shows left ventricular ejection fraction of 25%, LV end-diastolic diameter of 62 mm, moderate functional mitral regurgitation, and no thrombus. BNP is 1,850 pg/mL. She is started on guideline-directed medical therapy including sacubitril-valsartan, carvedilol, spironolactone, and dapagliflozin. Genetic testing reveals a truncating variant in the TTN gene. At 6-month follow-up, LVEF has improved to 40% but remains below normal. Which factor most strongly predicts her likelihood of complete LV recovery?", "options": ["Absence of late gadolinium enhancement on cardiac MRI", "Normalization of BNP levels", "Presence of the TTN truncating variant", "Baseline LVEF above 30%", "Multiparity status"], "answer": "A", "answer_index": 0, "explanation": "In peripartum cardiomyopathy, the absence of late gadolinium enhancement (LGE) on cardiac MRI is the strongest predictor of complete LV recovery, indicating absence of irreversible myocardial fibrosis. TTN truncating variants are actually associated with incomplete recovery and persistent LV dysfunction in PPCM, making option C incorrect. While BNP normalization and higher baseline LVEF are favorable, they are less predictive than LGE status. Multiparity is a risk factor for developing PPCM but does not predict recovery. LGE represents scar that cannot recover regardless of optimal medical therapy.", "generator_model": "claude-opus-4-5-20251101", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "Based on the clinical vignette, the patient has Peripartum Cardiomyopathy (PPCM) characterized by severe LV dysfunction (LVEF 25%) and LV dilatation (LVEDD 62 mm). Genetic testing identified a truncating variant in the *TTN* gene (*TTNtv*).\n\nThe question asks for the factor that most strongly predicts her likelihood of complete LV recovery.\n\n1.  Analyze the Prognostic Factors:\n    *   Baseline LVEF: Baseline LVEF is one of the strongest predictors of recovery in PPCM. An LVEF < 30% and LVEDD > 60 mm are statistically significant predictors of non-recovery (incomplete recovery). The patient has an LVEF of 25%, which predicts a poor likelihood of complete recovery. Option D (\"Baseline LVEF above 30%\") describes a favorable prognostic factor that this patient does not possess. Therefore, it is incorrect to select it as the factor predicting *her* likelihood.\n    *   Genetics (*TTN* truncating variant): Approximately 10-15% of women with PPCM carry *TTN* truncating variants. Major studies (e.g., *Ware et al., NEJM 2016*, IPAC study) have demonstrated that the presence of *TTN* truncating variants is associated with a significantly lower LVEF at 1-year follow-up and a reduced likelihood of complete LV recovery compared to women without these variants. The presence of this variant in this patient is a specific, identified factor that strongly predicts a lower probability of full recovery.\n    *   Late Gadolinium Enhancement (LGE): While the presence of LGE on cmR suggests fibrosis and a poorer prognosis, it is relatively rare in PPCM. Its absence is the typical finding and does not strongly stratify patients for *complete* recovery as well as baseline LVEF or genetic status in severe cases. Furthermore, the vignette does not state the MRI results regarding LGE; it only states the presence of the genetic variant.\n    *   BNP: While elevated BNP correlates with heart failure severity, the *normalization* of BNP is a marker of recovery during the course of treatment rather than a baseline predictor distinct from hemodynamic severity.\n    *   Multiparity: While a risk factor for developing PPCM, it is not as strong an independent predictor of LV recovery as echocardiographic parameters or genetic profile.\n\n2.  Conclusion:\n    The patient has a confirmed *TTN* truncating variant. The distinct teaching point regarding *TTN* variants in PPCM is that they define a subgroup of patients with a phenotype that overlaps with genetic Dilated Cardiomyopathy (DCM) unmasked by pregnancy, resulting in a poorer prognosis and a lower likelihood of complete myocardial recovery compared to \"classic\" PPCM. Thus, the presence of the variant is the strongest factor presented that predicts her (low) likelihood of complete recovery.\n\nThe answer is (C)"}]